Boston Hospital Trio awarded $25 million NIH grant to study critical limb ischemia

December 11, 2013

Boston, MA - A team of researchers from Brigham and Women's Hospital (BWH), Boston Medical Center (BMC) and Massachusetts General Hospital (MGH) has been awarded $25 million by the National Institutes of Health (NIH) to conduct a four-year, randomized clinical trial--the BEST-CLI Trial (Best Endovascular versus Best Surgical Therapy in Patients with Critical Limb Ischemia). The trial will compare traditional bypass surgery with the less invasive alternative of endovascular treatment for patients with critical limb ischemia (CLI).

The principal investigators of the BEST-CLI trial are Alik Farber, MD, division chief of Vascular and Endovascular Surgery at BMC; Matthew Menard, MD, co-director of Endovascular Surgery at BWH; and Kenneth Rosenfield, MD, section head of Vascular Medicine and Intervention at MGH.

CLI is the most severe form of peripheral arterial disease, which is caused by chronic inflammation and atherosclerotic plaque build-up in the arteries of the legs. Symptoms caused by reduced blood flow to the legs and feet include ischemic leg pain, non-healing wounds and gangrene. If untreated, CLI can often lead to leg amputation. The aging of the national population and the rising rate of diabetes have led to an increase in both peripheral arterial disease and CLI.

According to the study investigators, while both open surgery and endovascular interventions are used to treat CLI, it is not clear which approach works best in patients who are candidates for both treatment options.

"Currently, there is a lack of consistency and clarity as to what approach--minimally invasive endovascular or open surgery--is best for our patients," said Farber. "The BEST-CLI Trial will provide answers to many unanswered questions, most importantly what treatment works best for whom."

"The CLI population is an exceptionally complex and challenging group of patients to treat," added Menard. "In addition to providing much needed information on the functional outcomes and cost-effectiveness of the two treatment strategies being tested, the BEST-CLI Trial will provide a unique opportunity for interdisciplinary collaboration between all of the subspecialties currently providing care to CLI patients.

Added Rosenfield: "The BEST-CLI Trial will be a robust and rigorously conducted clinical trial which promises to greatly enhance our understanding of CLI--a devastating disorder that affects millions of Americans. We are grateful to the National Institutes of Health for recognizing the enormous impact of this scourge and look forward to expanding the evidence base to optimize care and outcomes for these patients with advanced cardiovascular disease."

The BEST-CLI trial will be highly innovative in both its design and its collaborative nature. It will provide, for the first time, urgently needed clinical guidance for CLI management by using: The trial will enroll 2,100 participants and be conducted at 120 clinical centers in the United States and Canada. The New England Research Institutes (Watertown, MA) will be serving as the data coordinating center.
Brigham and Women's Hospital (BWH) is a 793-bed nonprofit teaching affiliate of Harvard Medical School and a founding member of Partners HealthCare. BWH has more than 3.5 million annual patient visits, is the largest birthing center in New England and employs nearly 15,000 people. The Brigham's medical preeminence dates back to 1832, and today that rich history in clinical care is coupled with its national leadership in patient care, quality improvement and patient safety initiatives, and its dedication to research, innovation, community engagement and educating and training the next generation of health care professionals. Through investigation and discovery conducted at its Biomedical Research Institute (BRI), BWH is an international leader in basic, clinical and translational research on human diseases, and has more than 1,000 physician-investigators and renowned biomedical scientists and faculty supported by nearly $650 million in funding. For the last 25 years, BWH ranked second in research funding from the National Institutes of Health (NIH) among independent hospitals. BWH continually pushes the boundaries of medicine, including building on its legacy in transplantation by performing a partial face transplant in 2009 and the nation's first full face transplant in 2011. BWH is also home to major landmark epidemiologic population studies, including the Nurses' and Physicians' Health Studies and the Women's Health Initiative. For more information and resources, please visit BWH's online newsroom.

Boston Medical Center is a private, not-for-profit, 496-bed, academic medical center that is the primary teaching affiliate of Boston University School of Medicine. Committed to providing high-quality health care to all, the hospital offers a full spectrum of pediatric and adult care services including primary and family medicine and advanced specialty care with an emphasis on community-based care. Boston Medical Center offers specialized care for complex health problems and is a leading research institution. Boston Medical Center and Boston University School of Medicine are partners in the Boston HealthNet--15 community health centers focused on providing exceptional health care to residents of Boston. For more information, please visit

Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School. The MGH conducts the largest hospital-based research program in the United States, with an annual research budget of more than $775 million and major research centers in AIDS, cardiovascular research, cancer, computational and integrative biology, cutaneous biology, human genetics, medical imaging, neurodegenerative disorders, regenerative medicine, reproductive biology, systems biology, transplantation biology and photomedicine.

Brigham and Women's Hospital

Related Peripheral Arterial Disease Articles from Brightsurf:

Heart attack prevention lags for people with stroke, peripheral artery disease
Although all three conditions can lead to heart attack, people with stroke or peripheral artery disease were less likely to receive preventive treatments to prevent heart attack than people with coronary artery disease.

Work-related stress linked to increased risk for peripheral artery disease
People who reported work-related stress were more likely to be hospitalized for treatment of peripheral artery disease compared to those who did not report work-related stress.

Study maps landmarks of peripheral artery disease to guide treatment development
Novel biomedical advances that show promise in the lab often fall short in clinical trials.

Cocoa could bring sweet relief to walking pain for people with peripheral artery disease
Patients with peripheral artery disease (PAD) who consumed a flavanol-rich cocoa beverage three times daily for six months saw significant improvements in their 6-minute walking distance compared to a placebo, in a small, phase II randomized study.

15-year study finds treatment gaps exist for patients with peripheral arterial disease
In a new 15-year study, researchers at the Intermountain Healthcare Heart Institute in Salt Lake City found that patients with eripheral arterial disease may not be prescribed life-saving medications at the same rate as for other heart conditions.

Peripheral artery disease risk hinges on health factors and demographics, including race
The lifetime risk of lower-extremity peripheral artery disease (PAD), in which leg arteries narrow abnormally, is about 30 percent for black men and 28% for black women, with lower but still-substantial risks for Hispanics and whites, according to a study led by scientists at the Johns Hopkins Bloomberg School of Public Health.

Study quantifies smoking's strong link to peripheral artery disease
A new study led by researchers at the Johns Hopkins Bloomberg School of Public Health found that cigarette smoking boosts the risk of peripheral artery disease, and this elevated risk can persist up to 30 years after smoking cessation.

Smoking linked to higher risk of peripheral artery disease in African-Americans
African-Americans who smoke appear to be at greater risk for peripheral artery disease, or PAD, new research has found.

Cigarette smoking associated with increased risk of peripheral artery disease in African-Americans
African-Americans who smoke cigarettes are more likely than those who don't to have peripheral artery disease (PAD).

Undiplomatic immunity: Mutation causing arterial autoimmune disease revealed
Takayasu arteritis is an autoimmune disease resulting in chronic aortic inflammation leading to aneurysm or aortic regurgitation.

Read More: Peripheral Arterial Disease News and Peripheral Arterial Disease Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to